Laekna Stock Slides 4.5% as Market Doubts Clinical-Stage Biotech Viability
Laekna’s share plunges 4.55% as investors doubt its clinical‑stage prospects, underscoring the risk of low‑valuation biotech stocks lacking proven milestones.
3 minutes to read